Prolonged Nightly Fasting in Fibromyalgia
Primary Purpose
Fibromyalgia
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Prolonged Nightly Fasting
Health Education Control
Sponsored by
About this trial
This is an interventional treatment trial for Fibromyalgia focused on measuring intermittent fasting, chronic pain, quantitative sensory testing, sleep
Eligibility Criteria
Inclusion Criteria:
- age between 18 and 65
- female
- able to speak, write, and read English
- classified as having fibromyalgia based upon criteria established by the most up-to-date 2016 American College of Rheumatology (ACR) Criteria for Fibromyalgia
- has a smartphone.
Exclusion Criteria:
- history of eating disorders assessed by MINI Neuropsychiatric Interview
- self-report of chronic malignant pain (e.g., cancer, HIV) or systemic inflammatory disease (e.g., rheumatoid arthritis, ankylosing spondylitis, lupus)
- current use of melatonin or an immunosuppressant medication (e.g., steroids)
- currently pregnant, trying to get pregnant, or breastfeeding
- plans to relocate within the next 6 months
- has diabetes mellitus
- currently trying to lose weight
- currently routinely fasting more than 12 hours a night
- works night shifts
Sites / Locations
- Arizona State UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Prolonged Nightly Fasting (PNF)
Health Education Control (HEC)
Arm Description
Participants will engage in the PNF (14+ hours a night of fasting and no calorie containing food or beverages) for 8 weeks.
Participants in HEC group will receive weekly 15-minute videos (once weekly) focused on non-diet/non-fasting health educational content for 8 weeks.
Outcomes
Primary Outcome Measures
Feasibility--drop-out rate
Feasibility--adherence to intervention
The number of days prolonged nightly fasting was completed divided by the total number of treatment days
Acceptability of the intervention
It will be measured by the Global Satisfaction subscale in an adapted version of the Treatment Satisfaction Questionnaire for Medication. The scores are calculated for each of the subscales, which range from 0 to 100, with higher scores indicating higher patient satisfaction with the intervention.
Secondary Outcome Measures
Fatigue
Total score of Fatigue Severity Scale (ranges from 9-63; higher score means greater fatigue severity)
Fibromyalgia symtpoms
Total score from Revised Fibromyalgia Impact Questionnaire (FIQR) (ranges from 0-100; higher score means greater fibromyalgia symptom severity)
Cognitive Functioning
Total score from Montreal Cognitive Assessment (MoCA) (ranges from 0-30; higher score means better cognitive functioning)
Pain Severity
Average of 4 items from the Brief Pain Inventory; each rated on a 0 (no pain) to 10 (pain as bad as you can imagine); ratings are made of pain right now, typical pain, worst pain, and least pain during the past week.
Central Sensitization Index
Index of thermal temporal summation, mechanical temporal summation, conditioned pain modulation, and aftersensations (this is standardized Z-score)
Pain Interference
Average of 7 items from the Brief Pain Inventory; assessing the extent to which participant experienced that pain interfered with their (1) general activity, (2) mood; (3) walking ability; (4) normal walk; (5) relations with other people, (6) sleep, and (7) enjoyment of life
Inflammatory levels
IL-1β, IL-6, and TNF-α and C-Reactive Protein (CRP) levels
Total Sleep Time (TST)
TST is defined as the total number of minutes asleep between the time a participant goes to bed at night and the time a participant gets out of bed in the morning. TST will be derived from ambulatory EEG sleep monitoring.
Depressive symptoms
T-score from PROMIS Emotional Distress-Depression-Short Form
Full Information
NCT ID
NCT05581849
First Posted
October 12, 2022
Last Updated
October 20, 2023
Sponsor
Arizona State University
1. Study Identification
Unique Protocol Identification Number
NCT05581849
Brief Title
Prolonged Nightly Fasting in Fibromyalgia
Official Title
Prolonged Nightly Fasting in Individuals With Fibromyalgia: A Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 20, 2023 (Actual)
Primary Completion Date
May 19, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Arizona State University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The present randomized-controlled pilot trial will test the feasibility, acceptability, and preliminary efficacy of an 8-week prolonged nightly fasting (PNF) intervention protocol in 20 adults with fibromyalgia.
Aim 1: Evaluate feasibility and acceptability of the PNF intervention among participants with fibromyalgia.
Aim 2: Evaluate preliminary efficacy of PNF on pain severity and sensitivity, mood, sleep and inflammation.
Detailed Description
Fibromyalgia is characterized by chronic widespread pain, sleep disturbance, fatigue, negative mood, and cognitive dysfunction. It is estimated about 4 million individuals in the U.S. are affected by fibromyalgia, which results in high disability, lost productivity, and poor quality of life. Various medications have been tested, but findings suggest only small therapeutic effects with high side effects. First line evidence-based psychosocial interventions, such as cognitive behavioral therapy, also yield only small to moderate treatment effects and they require specialized personnel. Thus, there is a dire need to develop a novel approach to manage fibromyalgia symptoms with a high safety profile, are affordable, and are easily implemented by participants without extensive guidance and support from specialized personnel.
Prolonged nightly fasting (PNF) which is a type of time-restricted eating with no or minimal caloric intake for periods of time as few as 12 hours has been shown to promote various health benefits. PNF has also been demonstrated to be highly acceptable and adherable for adults with various clinical condition. Although some dietary patterns have been explored for their impact on pain, the effects of PNF on pain-related outcomes (e.g., pain severity, pain sensitivity), mood, sleep, and inflammation among individuals with fibromyalgia have not been examined. The present randomized-controlled pilot trial will test the feasibility, acceptability, and preliminary efficacy of an 8-week PNF intervention protocol in 20 adults with fibromyalgia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibromyalgia
Keywords
intermittent fasting, chronic pain, quantitative sensory testing, sleep
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Prolonged Nightly Fasting (PNF)
Arm Type
Experimental
Arm Description
Participants will engage in the PNF (14+ hours a night of fasting and no calorie containing food or beverages) for 8 weeks.
Arm Title
Health Education Control (HEC)
Arm Type
Active Comparator
Arm Description
Participants in HEC group will receive weekly 15-minute videos (once weekly) focused on non-diet/non-fasting health educational content for 8 weeks.
Intervention Type
Behavioral
Intervention Name(s)
Prolonged Nightly Fasting
Other Intervention Name(s)
Intermittent Fasting
Intervention Description
Participants will engage in 14+ hours a night of fasting and no calorie containing food or beverages for 8 weeks. Participants will be allotted one "cheat day" per week, during which they will not need to fast (or track their times)- the day may change weekly and will be based on participant preference. Study staff and study participants will engage in a weekly coaching call (via phone; 5-10 minutes). Weekly coaching calls will last through the duration of the 8-week intervention.
Intervention Type
Behavioral
Intervention Name(s)
Health Education Control
Intervention Description
Participants in this group will receive weekly 15-minute videos (once weekly) focused on non-diet/non-fasting health educational content for 8 weeks. Participants will be asked to review the video at their convenience, prior to their weekly coaching call (5-10 minutes) with the study staff. Weekly topics will be as follows: Week 1: Sleep hygiene, Week 2: Sun safety, Week 3: Home safety, Week 4: Driving safety, Week 5: Hydration, Week 6: Dental health, Week 7: Working environment, Week 8: Communication.
Primary Outcome Measure Information:
Title
Feasibility--drop-out rate
Time Frame
At 8 weeks post-treatment
Title
Feasibility--adherence to intervention
Description
The number of days prolonged nightly fasting was completed divided by the total number of treatment days
Time Frame
At 8 weeks post-treatment
Title
Acceptability of the intervention
Description
It will be measured by the Global Satisfaction subscale in an adapted version of the Treatment Satisfaction Questionnaire for Medication. The scores are calculated for each of the subscales, which range from 0 to 100, with higher scores indicating higher patient satisfaction with the intervention.
Time Frame
At 8 weeks post-treatment
Secondary Outcome Measure Information:
Title
Fatigue
Description
Total score of Fatigue Severity Scale (ranges from 9-63; higher score means greater fatigue severity)
Time Frame
Baseline and 8 weeks post-treatment
Title
Fibromyalgia symtpoms
Description
Total score from Revised Fibromyalgia Impact Questionnaire (FIQR) (ranges from 0-100; higher score means greater fibromyalgia symptom severity)
Time Frame
Baseline and 8 weeks post-treatment
Title
Cognitive Functioning
Description
Total score from Montreal Cognitive Assessment (MoCA) (ranges from 0-30; higher score means better cognitive functioning)
Time Frame
Baseline and 8 weeks post-treatment
Title
Pain Severity
Description
Average of 4 items from the Brief Pain Inventory; each rated on a 0 (no pain) to 10 (pain as bad as you can imagine); ratings are made of pain right now, typical pain, worst pain, and least pain during the past week.
Time Frame
Baseline and 8 weeks post-treatment
Title
Central Sensitization Index
Description
Index of thermal temporal summation, mechanical temporal summation, conditioned pain modulation, and aftersensations (this is standardized Z-score)
Time Frame
Baseline and 8 weeks post-treatment
Title
Pain Interference
Description
Average of 7 items from the Brief Pain Inventory; assessing the extent to which participant experienced that pain interfered with their (1) general activity, (2) mood; (3) walking ability; (4) normal walk; (5) relations with other people, (6) sleep, and (7) enjoyment of life
Time Frame
Baseline and 8 weeks post-treatment
Title
Inflammatory levels
Description
IL-1β, IL-6, and TNF-α and C-Reactive Protein (CRP) levels
Time Frame
Baseline and 8 weeks post-treatment
Title
Total Sleep Time (TST)
Description
TST is defined as the total number of minutes asleep between the time a participant goes to bed at night and the time a participant gets out of bed in the morning. TST will be derived from ambulatory EEG sleep monitoring.
Time Frame
Baseline and 8 weeks post-treatment
Title
Depressive symptoms
Description
T-score from PROMIS Emotional Distress-Depression-Short Form
Time Frame
Baseline and 8 weeks post-treatment
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age between 18 and 65
female
able to speak, write, and read English
classified as having fibromyalgia based upon criteria established by the most up-to-date 2016 American College of Rheumatology (ACR) Criteria for Fibromyalgia
has a smartphone.
Exclusion Criteria:
history of eating disorders assessed by MINI Neuropsychiatric Interview
self-report of chronic malignant pain (e.g., cancer, HIV) or systemic inflammatory disease (e.g., rheumatoid arthritis, ankylosing spondylitis, lupus)
current use of melatonin or an immunosuppressant medication (e.g., steroids)
currently pregnant, trying to get pregnant, or breastfeeding
plans to relocate within the next 6 months
has diabetes mellitus
currently trying to lose weight
currently routinely fasting more than 12 hours a night
works night shifts
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chung Jung Mun, Ph.D.
Phone
602-496-0809
Email
ChungJung.Mun@asu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chung Jung Mun, Ph.D.
Organizational Affiliation
Arizona State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Arizona State University
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85004
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Theresa Jorgensen, BA, BS, RDCS, RDMS, RVT
First Name & Middle Initial & Last Name & Degree
Chung Jung Mun, Ph.D.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Prolonged Nightly Fasting in Fibromyalgia
We'll reach out to this number within 24 hrs